New publications! Link in post.

r/covidlonghaulers user u/GURPSenjoyer shared a PolyBio-supported study: in some long COVID patients, persistently activated virus-specific CD8+ T cells targeting SARS-CoV-2 and herpesviruses (EBV/CMV) were found, suggesting viral persistence/reactivation driving chronic inflammation. In the comments, u/barweis proposed CAR-T/monoclonal antibody/miRNA interventions, u/Pak-Protector mentioned Invivyd monoclonal antibodies, and u/Busy_Land_1885 and u/CANfilms asked "should we try an antiviral course"—most replies said prior trials of various antivirals (including extended Paxlovid) showed no benefit. Factually: the study is real, published by Gladstone/UCSF and other teams in Cell Reports Medicine, with a bioRxiv preprint (Painter et al., 2026-10-14); about 40% of long COVID patients showed persistent spike-specific CD8 activation that did not cross-react with influenza, supporting the "antigen persistence" hypothesis; however, it is an observational immunoprofiling analysis, not yet translated into an approved therapy, and clinical benefit of antiviral treatment still lacks a positive RCT.

Checked ✔ (PolyBio-supported study, Gladstone/UCSF et al., Cell Reports Medicine + bioRxiv Painter 2026-10-14; ~40% of LC patients show persistent spike-specific CD8 activation, supporting the antigen persistence hypothesis; observational, not translated into an approved therapy).